• PHP13 MARKET AUTHORIZATION (MA) AND REIMBURSEMENT- ANALYSIS OF THE POST-MA TIMELINES AND THE ACCESS TO NEW MEDICINES IN BELGIUM

    Nov 1, 2008, 00:00

  • PCV8 CLINICAL AND ECONOMIC IMPACT OF DRUG-ELUTING STENT AND BARE METAL STENT IN HONG KONG-A SINGLE CENTRE 'REALWORLD' EXPERIENCE

    Nov 1, 2008, 00:00

  • PHP34 COSTS ASSOCIATED TO ADDITIONAL TEMPORAL SICK LEAVE DAYS IN THE IMSS

    Nov 1, 2008, 00:00

  • PMC5 A MISSING DATATHRESHOLD AS APPLIED TO HEALTH OUTCOMES DATA- DIFFERENTIAL IMPLICATIONS FOR COST-UTILITY ANALYSIS BY DIAGNOSIS

    Nov 1, 2008, 00:00

  • PCV32 ECONOMIC EVALUATION OF ATORVASTATIN AND ROSUVASTATIN USING HEAD-TO-HEAD RANDOMIZED CONTROLLED TRIAL WITH UP-TITRATION OF DRUG DOSES TO OBTAIN THERAPEUTIC TARGETS FOR LDL-CHOLESTEROL

    Nov 1, 2008, 00:00

  • PCN46 COST-MINIMIZATION ANALYSIS OF CAPECITABINE VERSUS UFT/LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER (MCRC) IN BRAZIL

    Nov 1, 2008, 00:00

  • PCV39 COST-EFFECTIVENESS OF NIASPANVERSUS ZETIA AS ADD-ON TREATMENTTO STATIN THERAPY IN HIGH-RISK PATIENTS

    Nov 1, 2008, 00:00

  • PND4 GLATIRAMER ACETATE VERSUS INTERFERON BETA-1B FOR SUBCUTANEOUS ADMINISTRATION- A COMPARISON OF OUTCOMES AMONG MULTIPLE SCLEROSIS PATIENTS

    Nov 1, 2008, 00:00

  • PMC20 QUANTITATIVE APPROACH TO DETERMINE THE EFFECT OF SEGMENTATION ON REVENUE GENERATION, POSITIONING AND PRICING OF PHARMACEUTICALS

    Nov 1, 2008, 00:00

  • PSS9 SENSITIVE SCALP- AN EPIDEMIOLOGICAL APPROACH

    Nov 1, 2008, 00:00

  • PMH27 HEALTH SERVICE EXPENDITURES FOR PATIENTS WITH A DIAGNOSIS OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) IN GERMANY-AN AGE AND GENDER SPECIFIC ANALYSIS

    Nov 1, 2008, 00:00

  • PSS25 COST-EFFECTIVENESS OF ETANERCEPT AND EFALIZUMAB IN THE MANAGEMENT OF MODERATE AND SEVERE PLAQUE PSORIASIS

    Nov 1, 2008, 00:00

  • PMH56 PATTERNS OF FIRST VISITS TO PSYCHIATRIC CLINICS IN TAIWAN- A NATIONWIDE STUDY, 2006

    Nov 1, 2008, 00:00

  • PMC58 THE POTENTIAL PENALTY FOR NOT SAMPLING FROM THE RISK SET IN NESTED CASE-CONTROL DESIGNS- EVIDENCE FROM SIMULATED DATA

    Nov 1, 2008, 00:00

  • PSS54 EVALUATION OF TREATMENT SATISFACTION WITH ETANERCEPT VERSUS ALTERNATIVE TREATMENTS FOR PSORIASIS- A PATIENT SURVEY ACROSS NINE EUROPEAN COUNTRIES

    Nov 1, 2008, 00:00

  • PCV106 PATIENT OUTCOMES AND HEALTH ECONOMICS ASSOCIATED WITH THE USE OF OCTYLCYANOACROLATE TOPICAL SKIN ADHESIVE IN CABG SURGERY

    Nov 1, 2008, 00:00

  • PMC26 PREDICTING HEALTH SERVICE UTILIZATION WITH THE PCS AND MCS OF THE SF-36

    Nov 1, 2008, 00:00

  • PMS20 IMPACT OF MEDICATION NON-COMPLIANCE AND NON-PERSISTENCE ON PHARMACOECONOMIC EVALUATIONS IN OSTEOPOROSIS

    Nov 1, 2008, 00:00

  • PSS47 A TOPIC DERMATITIS AND THERMAL THERAPY- EVALUATION IN CHILDREN UNDER 15

    Nov 1, 2008, 00:00

  • PCV67 CLINICAL CHARACTERISTICS, MEDICATION AND COSTS IN ACUTE HEART FAILURE PATIENTS IN THE CZECH REPUBLIC

    Nov 1, 2008, 00:00

  • PCN60 CLINICAL AND ECONOMIC ASPECTS OF THE MANAGEMENT OF PATIENTS WITH MALIGNANT ASCITES-RESULTS OF A PILOT STUDY

    Nov 1, 2008, 00:00

  • PCV90 THE CONTRIBUTION OF THE MEASUREMENT OF TREATMENT ACCEPTABILITY TO UNDERSTAND PATIENTS ADHERENCE TO LONG-TERM TREATMENTS. RESULTS FROM A FEASIBILITY STUDY CONDUCTED WITH IN FINE PHARMA- A COMMUNITY-PHARMACY NETWORK DEDICATED TO PHARMAC ...

    Nov 1, 2008, 00:00

  • PCV52 COST-UTILITY ANALYSIS OF HOMETELEMONITORING IN ELDERLY PATIENTS WITH CHRONIC HEART FAILURE

    Nov 1, 2008, 00:00

  • IN1 COST EFFECTIVENESS ANALYSIS OF REYATAZ VERSUS KALETRA IN THE TREATMENT OF NAVE HIV PATIENTS IN ITALY

    Nov 1, 2008, 00:00

  • CV2 A NEW MEASURE FOR ASSESSING HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN PATIENTS WITH A TRIAL FIBRILLATION-AF-QOL

    Nov 1, 2008, 00:00

  • CN8 AN ECONOMIC EVALUATION OF DASATINIB (SPRYCEL) IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) IN CENTRAL AND EASTERN EUROPE

    Nov 1, 2008, 00:00

  • PCN73 DEVELOPING A COMPREHENSIVE COSTS TOOLKIT TO FACILITATE ECONOMIC EVALUATIONS OF CANCER CARE IN FRANCE

    Nov 1, 2008, 00:00

  • PCV17 COLD AND INACTIVITY- THE ULTIMATE FACTORS FOR HEART ATTACK

    Nov 1, 2008, 00:00

  • PHP1 PATIENTS PREFERENCES FOR AND PRICE ELASTICITY OF GENERIC AND BRANDED OVER-THE-COUNTER MEDICINES-AN ADAPTIVE CONJOINT ANALYSIS (ACA) APPROACH

    Nov 1, 2008, 00:00

  • PRS36 WILLINGNESS TO PAY FOR CAREGIVERS OF PEDIATRIC ASTHMATIC PATIENTS IN KOREA

    Nov 1, 2008, 00:00

  • PCN45 ECONOMIC ANALYSIS OF THE CLINICAL OUTCOMES OF SURGICAL THERAPY (COST) TRIAL COMPARING LAPAROSCOPICALLY-ASSISTED COLECTOMY (LAC) WITH OPEN COLECTOMY (OC) FOR COLON CANCER

    Nov 1, 2008, 00:00

  • PDB47 THE SUITABILITY OF POLYCYSTIC OVARY SYNDROME-SPECIFIC QUESTIONNAIRES FOR MEASURING THE IMPACT OF PCOS ON QUALITY OF LIFE IN CLINICAL TRIALS

    Nov 1, 2008, 00:00

  • PMC16 EXPENSIVE DRUGS FOR RARE DISORDERS AND THE LOGIC OF COST-EFFECTIVENESS

    Nov 1, 2008, 00:00

  • CASE2 DOTECHNOLOGY EVALUATIONS BASED ON EVIDENCE FROM CONDITIONAL FUNDING LEAD TO AN INCREASE IN POLICY FORMATION?- FINDINGS FROM, AND IMPLICATIONS OF, ONTARIOS EVIDENCE-BASED HTA PROCESS

    Nov 1, 2008, 00:00

  • PMC14 A FRAMEWORK FOR REAL-WORLD ECONOMIC EVALUATION BY INCORPORATING IMPLEMENTATION PARAMETERS

    Nov 1, 2008, 00:00

  • PCV31 ORAL ANTICOAGULATION AFTER MAJOR HIP OR KNEE REPLACEMENT SURGERIES

    Nov 1, 2008, 00:00

  • PIN1 A BAYESIAN META-ANALYSIS OF THE EFFICACY OF SIX ANTIMICROBIAL AGENTS FOR CONFIRMED STAPHYLOCOCCUS AUREUS COMPLICATED SKIN AND SOFT-TISSUE INFECTIONS (CSSTIS)

    Nov 1, 2008, 00:00

  • PCV26 TREATING TO LOWER LDL-C TARGETS- ESTIMATING THE NUMBER AND COST OF CARDIOVASCULAR EVENTS AVOIDED FOR REGIONAL HEALTH ECONOMIES IN ENGLAND, SCOTLAND, WALES AND NORTHERN IRELAND

    Nov 1, 2008, 00:00

  • PMS63 PATIENT REPORTED OUTCOMES OF DIFFERENT SURGICAL PROCEDURES IN PATIENTS WITH CARTILAGE DEFECTS OF THE KNEE AFTER 1 TO 5YEARS

    Nov 1, 2008, 00:00

  • PCN16 ANALYSIS OF COSTS AND CONSEQUENCES IN CANCER PATIENTS RECEIVING CAPECITABINE

    Nov 1, 2008, 00:00

  • PCN6 MODELING LUNG AND BREAST CANCER INCIDENCE IN SPAIN- A ZERO INFLATED NEGATIVE BINOMIAL REGRESSION APPROACH

    Nov 1, 2008, 00:00

  • PMS26 COST-EFFECTIVENESS ANALYSIS OF RHBMP-2 IN THE TREATMENT OF OPENTIBIA FRACTURES IN THE NETHERLANDS

    Nov 1, 2008, 00:00

  • PND26 ARE THERE DIFFERENCES IN PATIENT SATISFACTION WITH INSOMNIA MEDICATIONS? PILOT RESULTS FROM A NOVEL REGISTRY

    Nov 1, 2008, 00:00

  • PCV16 MONITORING POTENTIAL DRUG-DRUG INTERACTIONS-AN APPLICATION FOR PRESCRIPTION CLAIMS DATABASES

    Nov 1, 2008, 00:00

  • PRS34 QUALITY OF LIFE DURING ACUTE EXACERBATIONS OF COPD- COMPARING EQ-5D, SF-12 AND SGRQ

    Nov 1, 2008, 00:00

  • PCN62 ECONOMIC BURDEN OF TOXICITIES ASSOCIATED WITH SALVAGE TREATMENT IN ADVANCED AND METASTATIC BREAST CANCER

    Nov 1, 2008, 00:00

  • PSY38 IMPACT OF TENSION HEADACHE ON WORK PRODUCTIVITY LOSS AND ACTIVITY IMPAIRMENT

    Nov 1, 2008, 00:00

  • PMS29 COSTS AVOIDED BY DIAGNOSING FIBROMYALGIA IN SPANISH PATIENTS

    Nov 1, 2008, 00:00

  • PSY7 THE BUDGETARY IMPACT OF INCLUDING LAPAROSCOPIC ADJUSTABLE GASTRIC BANDING AS A COVERED SURGICAL TREATMENT FOR MORBIDLY OBESE ADULTS IN A MANAGED CARE POPULATION

    Nov 1, 2008, 00:00

  • PIN27 COST-EFFECTIVENESS ANALYSIS OF CASPOFUNGIN VERSUS AMPHOTERICIN B, VORICONAZOLE, AND ANIDULAFUNGIN IN THE TREATMENT OF INVASIVE CANDIDIASIS

    Nov 1, 2008, 00:00

  • PMC51 UTILITIES OF THE EQ-5D-TRANSFERABLE OR NOT? INFLUENCE OF THE NATIONAL VALUE SETS OF THE EQ-5D ON THE INCREMENTAL UTILITIES OF TWO HEALTH STATES

    Nov 1, 2008, 00:00

  • PSS34 MODELLING THE LONG-TERM CLINICAL OUTCOMES OF MEDICAL MANAGEMENT OF PRIMARY OPEN ANGLE GLAUCOMA AND OCULAR HYPERTENSION

    Nov 1, 2008, 00:00

  • PHC3 COST AND QUALITY IMPROVEMENTS ASSOCIATED WITH MINIMALLY INVASIVE SURGERY (MIS) TOTAL HIP ARTHROPLASTY (THA)

    Nov 1, 2008, 00:00

  • PCV116 THE ANALYSIS OF STATINS USAGE IN CROATIA DURING THE FIVE-YEAR PERIOD

    Nov 1, 2008, 00:00

  • PG119 THE COST-UTILITY OF LIVER DISEASE DIAGNOSIS- ASSESSING GP DECISIONS FOR PATIENTS WITH ABNORMAL LIVER FUNCTION TESTS AND NO OBVIOUS LIVER DISEASE

    Nov 1, 2008, 00:00

  • PSS14 DRY SKIN- AN EPIDEMIOLOGICAL APPROACH

    Nov 1, 2008, 00:00

  • PIN9 BUDGET IMPACT ANALYSIS OF INTRODUCING ROUTINE VACCINATION WITH A QUADRIVALENT HPV-VACCINE IN NORWAY

    Nov 1, 2008, 00:00

  • MS4 GOLIMUMAB SIGNIFICANTLY IMPROVES PRODUCTIVITY IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS- RESULTS FROM THE PHASE 3 GO-RAISE STUDY

    Nov 1, 2008, 00:00

  • PSY50 ASSESSING THE VALUE OF 24-HOUR CHRONIC PAIN CONTROL FROM THE PATIENT PERSPECTIVE- DO EXISTING PATIENT-REPORTED OUTCOMES INSTRUMENTS ADEQUATELY COVER THE RELEVANT CONCEPTS RELATED TO 24-HOUR CHRONIC PAIN CONTROL?

    Nov 1, 2008, 00:00

  • PIN54 ADAPTATION CALIBRATION OF A UK MODEL OF MENINGOCOCCAL DISEASE TO THE US SETTING

    Nov 1, 2008, 00:00

  • PSY26 COST OF TYROSINAEMIA TYPE ONE IN POLAND IN 2006

    Nov 1, 2008, 00:00

  • MD3 COST-EFFECTIVENESS OF LUMBAR DISC ARTHROPLASTY VERSUS LUMBAR FUSION FROM A HEALTH CARE SYSTEMS PERSPECTIVE IN AUSTRIA

    Nov 1, 2008, 00:00

  • PMC49 COMPARISON OF HEALTH LOCUS OF CONTROL BETWEEN PHYSICIANS AND THE GENERAL PUBLIC- MULTI-GROUP STRUCTURAL EQUATION MODELING

    Nov 1, 2008, 00:00

  • PMH7 PREVALENCE OF POTENTIAL MEDICATION INTERACTIONS WITH ANTIPSYCHOTICS VIA CYTOCHROME P450 IN PATIENTS WITH SCHIZOPHRENIA IN GERMANY

    Nov 1, 2008, 00:00

  • PMS53 PUBLIC HEALTH OBJECTIVE- THE QUALITY OF LIFE OF SUFFERERS OF OSTEOARTHRITIS FINALLY TAKEN INTO CONSIDERATION

    Nov 1, 2008, 00:00

  • PSS27 COST-EFFECTIVENESS OF THREE INTRA-OCULAR LENSES AFTER CATARACT SURGERY IN THE NETHERLANDS- RESTOR, ARRAY-SA40 AND A MONOFOCAL

    Nov 1, 2008, 00:00

  • PHC1 TREATMENT OF DISCOGENIC LOW BACK PAIN WITH INTRADISCAL ELECTROTHERMAL THERAPY [IDET], A MINIMALLY INVASIVE, LOW COST ALTERNATIVE TO OPEN SURGERY- A PROSPECTIVE 24-MONTH OUTCOMES STUDY IN 50 CONSECUTIVE PATIENTS

    Nov 1, 2008, 00:00

  • PMC28 STATUS-QUO BIAS IN STATED-CHOICE STUDIES- IS IT REAL?

    Nov 1, 2008, 00:00

  • PG116 DIRECT MEDICAL COSTS OF GERD AND ASSOCIATED FACTORS

    Nov 1, 2008, 00:00

  • PG134 PATIENT PREFERENCES FOR CROHNS DISEASE MAINTENANCE THERAPY- A DISCRETE CHOICE EXPERIMENT

    Nov 1, 2008, 00:00

  • PIH18 RELIABILITY, AND VALIDITY OF THE FATIGUE SYMPTOM INVENTORY

    Nov 1, 2008, 00:00

  • PRS13 THE COST-EFFECTIVENESS OF VARENICLINE IN SMOKING CESSATION IN DENMARK

    Nov 1, 2008, 00:00

  • PMC19 COST-EFFECTIVENESS ANALYSES OF BEHAVIORAL INTERVENTIONS- TOWARDS A MORE REALISTIC COST-EFFECTIVENESS RATIO BY INCLUDING INTERMEDIATE OUTCOME MEASURES

    Nov 1, 2008, 00:00

  • PMH2 DIRECT AND INDIRECT TREATMENT EFFECTS ON SLEEP DISTURBANCE IN GENERALIZED ANXIETY DISORDER- A STATISTICAL MEDIATION MODEL ANALYSIS

    Nov 1, 2008, 00:00

  • PHP45 THE REIMBURSEMENT OF ORPHAN DRUGS ACROSS EUROPE

    Nov 1, 2008, 00:00

  • PCV87 PERSISTENCE WITH AMIODARONE OR SOTALOL AND ITS IMPACT ON A TRIAL FIBRILLATION-RELATED HOSPITALIZATIONS AND CARDIOVERSIONS

    Nov 1, 2008, 00:00

  • PCN64 SHIFT OF PUBLIC HEALTH CARE EXPENDITURES FOR PALLIATIVE CANCER PATIENTS FROM INPATIENT TO OUTPATIENT EFFECTED BY HOME CARE SUPPORT TEAMS PROVIDED BY A UNIVERSITY HOSPITAL IN AUSTRIA

    Nov 1, 2008, 00:00

  • PHP57 INAPPROPRIATE SEDATION IN ICUS- EVIDENCE FROM THE LITERATURE

    Nov 1, 2008, 00:00

  • PHP17 SOURCES OF INFORMATION ON DRUGS USED BY GENERAL PRACTITIONERS IN POLAND

    Nov 1, 2008, 00:00

  • PIN14 USING A DECISION SIMULATION MODELTO EVALUATE THE COST-EFFECTIVENESS OF THE TREATMENT OF NUCLEOSIDE-NAVE HBE-ANTIGEN NEGATIVE CHB PATIENTS IN ITALY WITH ENTECAVIR AND TEN OF OVIR

    Nov 1, 2008, 00:00

  • PRS37 RACIAL DISPARITIES IN UTILIZATION OF ASTHMA CONTROLLER DRUGTHERAPY

    Nov 1, 2008, 00:00

  • PSY4 EPIDEMIOLOGY OF IDIOPATHICTHROMBOCYTOPENIC PURPURA IN BELGIUM ASSESSED USING HOSPITAL RECORDS

    Nov 1, 2008, 00:00

  • PSY59 A POPULATION STUDY ON THE AGE-SPECIFIC RELATIONSHIP BETWEEN BODY MASS INDEX, METABOLIC DISORDERS, AND UTILIZATION OF AMBULATORY SERVICES

    Nov 1, 2008, 00:00

  • PMC48 UPDATE OF TRENDS IN THE INCLUSION OF PATIENT-REPORTED OUTCOME (PRO) DATA IN APPROVED DRUGS LABELING BY FDA AND EMEA

    Nov 1, 2008, 00:00

  • PCN103 HETEROGENEITY IN THE APPROACH TAKEN TO CONDUCTING CHART AUDITS IN AUSTRALIAN HOSPITALS

    Nov 1, 2008, 00:00

  • PSS23 TOPICAL TACROLIMUS FOR THE TREATMENT OF A TOPIC DERMATITIS- A SYSTEMATIC REVIEW WITH META-ANALYSES

    Nov 1, 2008, 00:00

  • PSY46 PATIENT-REPORTED OUTCOMES (PRO) AND ECONOMICS OF MIGRAINE IN GERMANY

    Nov 1, 2008, 00:00

  • PHP55 CHIRALTY AND HOSPITAL FORMULARY- A SECOND LIFE FOR A BLOCKBUSTER

    Nov 1, 2008, 00:00

  • PHC10 PROPHYLAXIS WITH RIVAROXABAN AGAINST VENOUS THROMBOEMBOLISM (VTE)-A COST-CONSEQUENCE ANALYSIS FROM THE PERSPECTIVE OF THE ITALIAN HEALTH CARE SERVICE

    Nov 1, 2008, 00:00

  • PCN54 HOSPITAL BURDEN OF DISEASE ASSOCIATED WITH METASTATIC BONE DISEASE (MBD) AND SKELETAL-RELATED EVENTS (SRES) IN PATIENTS WITH BREAST CANCER (BC) AND PROSTATE CANCER (PC) IN THE UNITED KINGDOM (UK)

    Nov 1, 2008, 00:00

  • PHC8 COST-EFFECTIVENESS OF RIVAROXABANVERSUS ENOXAPARIN FORTHROMBOPROPHYLAXIS AFTER TOTAL KNEE REPLACEMENT IN THE UK AND SPAIN

    Nov 1, 2008, 00:00

  • PHP25 EVALUATING AN ONLINE FREEWARE CALCULATOR AND PLOTTER FOR ANALYZING COST EFFECTIVENESS DATA FOR FORMULARY DRUG CLASSES

    Nov 1, 2008, 00:00

  • PDB22 COST-EFFECTIVENESS OF INSULIN GLARGINE COMPARED TO INSULIN DETEMIR FOR TYPE 1 (T1DM) AND TYPE 2 DIABETES MELLITUS (T2DM) PATIENTS IN THE CANADIAN PAYER SETTING

    Nov 1, 2008, 00:00

  • PMC33 THE ROLE OF RANKING DATA IN HEALTHVALUATION

    Nov 1, 2008, 00:00

  • PCN105 MEDICARE PART DS MARKET IMPACT ON UTILIZATION, AVERAGE RETAIL PRICE AND OUT-OF-POCKET SPENDING FOR ORAL CHEMOTHERAPEUTICS AND A COMPARATIVE MARKET BASKET OF DRUGS

    Nov 1, 2008, 00:00

  • PDB16 THE COST-UTILITY AND BUDGET IMPACT ANALYSIS OF SITAGLIPTIN (JANUVIA) IN TYPE 2 DIABETES IN POLAND

    Nov 1, 2008, 00:00

  • CV4 COST-EFFECTIVENESS ANALYSIS OF IVABRADINE IN STABLE ANGINA PATIENTS IN THE NETHERLANDS

    Nov 1, 2008, 00:00

  • PCN19 COST EFFECTIVENESS OF CETUXIMAB IN FIRST LINE TREATMENT OF METASTATIC COLORECTAL CANCER- A MODELLING APPROACH FOR THE UK

    Nov 1, 2008, 00:00

  • PSS50 DEVELOPMENT OF AN INSTRUMENT FOR ASSESSING HEALTH RELATED QUALITY OF LIFE IN PATIENTS WITH CHRONIC URTICARIA

    Nov 1, 2008, 00:00

  • PCN48 COST-MINIMIZATION ANALYSIS OF XELOXVERSUS FOLFOX-6 IN THE FIRST LINE TREATMENT OF METASTATIC COLORECTAL CANCER IN BRAZIL

    Nov 1, 2008, 00:00

  • PRS1 SMOKING, ASTHMA AND COPD IN ADULTS- A TOO FREQUENT RELATION

    Nov 1, 2008, 00:00

  • PG122 ASSESSING THE PATIENT-REPORTED IMPACT OF USING BOWEL CLEANSING PREPARATIONS

    Nov 1, 2008, 00:00

  • PCASE2 PHARMACOECONOMIC APPLICATIONS IN FORMULARY MANAGEMENT- A CASE STUDY OF CETUXIMAB AT A MAJOR ACADEMIC CANCER CENTER

    Nov 1, 2008, 00:00

  • PCV58 COSTS OF CORONARY ARTERY DISEASE (CAD) IN POLAND

    Nov 1, 2008, 00:00

  • PSS1 RISK OF PSYCHIATRIC DISORDERS AND HEALTH CARE EXPENDITURES AMONG PATIENTS WITH MODERATE TO SEVERE PSORIASIS

    Nov 1, 2008, 00:00

  • PMC21 ASSESSING THE RELATIONSHIP BETWEEN COMPUTATIONAL SPEED AND PRECISION- A CASE STUDY USING A DISCRETE EVENT SIMULATION MODEL IN DIABETES CARE

    Nov 1, 2008, 00:00

  • PSS26 PHARMACOECONOMIC EVALUATION OF RANIBIZUMAB IN THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION IN AUSTRIA

    Nov 1, 2008, 00:00

  • PDB20 LONG-TERM COST-EFFECTIVENESS OF INSULIN DETEMIR COMPARED TO NEUTRAL PROTAMINE HAGEDORN INSULIN IN PATIENTS WITH TYPE 1 DIABETES USING A BASAL-BOLUS REGIMEN IN BELGIUM, FRANCE, GERMANY, ITALY AND SPAIN

    Nov 1, 2008, 00:00

  • PMC46 SHOULDWE BE CONSIDERING COMPONENTS OF SOCIAL COGNITION MODELS TO IMPROVE ADHERENCE TO IMMUNOSUPPRESSION MEDICATION?

    Nov 1, 2008, 00:00

  • PSS52 SCORING AND PSYCHOMETRIC PROPERTIES OF THE EYE-DROP SATISFACTION QUESTIONNAIRE (EDSQ)

    Nov 1, 2008, 00:00

  • PSY33 CLINICAL AND ECONOMIC OUTCOMES ASSOCIATED WITH BLOODTRANSFUSION DURING INPATIENT HOSPITALIZATION- AN ANALYSIS OF THE 2004 HEALTH CARE COST AND UTILIZATION PROJECT NATIONWIDEINPATIENT SAMPLE DATABASE

    Nov 1, 2008, 00:00

  • PMH28 THE ECONOMICS OF SCHIZOPHRENIA IN GERMANY AND THE POTENTIAL OF LONG ACTING SECOND GENERATION DEPOT TREATMENT

    Nov 1, 2008, 00:00

  • PMS64 DIFFERENCES IN QUALITY OF LIFE ACCORDING TO THE REPLACED JOINT

    Nov 1, 2008, 00:00

  • PIN24 ECONOMIC AND CLINICAL IMPACT OF IMPLEMENTATION OF AN ACELLULAR PERTUSSIS VACCINE IN CANADA

    Nov 1, 2008, 00:00

  • PG12 UNCONTROLLED GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)- FINDINGS FROM A UK MULTICENTRE, CROSS-SECTIONAL STUDY

    Nov 1, 2008, 00:00

  • PSY40 BURDEN OF FIBROMYALGIA TO THE UK NATIONAL HEALTH SERVICE (NHS)

    Nov 1, 2008, 00:00

  • PCV100 METFORMIN FOR THE TREATMENT OF METABOLIC DISTURBANCES AND CARDIOVASCULAR RISK FACTORS INWOMEN WITH POLYCYSTIC OVARY SYNDROME- A SYSTEMATIC REVIEW AND META-ANALYSIS

    Nov 1, 2008, 00:00

  • PMC7 SELF-REPORT VERSUS CAREGIVER REPORT OF HEALTH CARE UTILIZATION- IMPACT ON COST AND COST-EFFECTIVENESS

    Nov 1, 2008, 00:00

  • PSY48 EPIDEMIOLOGY OF HEREDITARY COAGULOPATHIES IN RUSSIA- PATIENT-REPORTED DATA. INTERMEDIATE RESULTS. PART 2

    Nov 1, 2008, 00:00

  • PSS20 SENSITIVE SKINS IN ITALY- AN EPIDEMIOLOGICAL APPROACH

    Nov 1, 2008, 00:00

  • PG127 PSYCHOMETRIC VALIDATION OF TRANSLATION TO SPANISH OF THE REFLUX DISEASE QUESTIONNAIRE (RDQ) AND GASTROINTESTINAL IMPACT SCALE IN PATIENTS WITH GASTROESOPHAGEAL REFLUX DISEASE (GERD)

    Nov 1, 2008, 00:00

  • PCN43 MODELING THE COST-EFFECTIVENESS OF PROSTATE CANCERTREATMENT WITH PARTICLE THERAPY

    Nov 1, 2008, 00:00

  • PSS13 HAIR LOSS- AN EPIDEMIOLOGICAL APPROACH

    Nov 1, 2008, 00:00

  • OR1 EXAMINING ASSOCIATION BETWEEN PATIENT-REPORTED OUTCOMES AND CLINICAL OUTCOMES USING PROBIT REGRESSION ANALYSIS

    Nov 1, 2008, 00:00

  • PCV33 COST OF OUTPATIENT HYPERTENSION PHARMACOTHERAPY-COMPARATIVE STUDY BETWEEN BULGARIA AND SERBIA

    Nov 1, 2008, 00:00

  • PMC30 THE IMPACT OF INITIAL DISEASE SEVERITY- AN APPLICATION TO EXISTING HEALTH ECONOMICS MODELS

    Nov 1, 2008, 00:00

  • PCN31 ECONOMIC EVALUATION OF CLODRONATE AND ZOLENDRONATE IN PATIENTS DIAGNOSED WITH METASTATIC BONE DISEASE FROM THE PERSPECTIVE OF THIRD PARTY PAYORS IN BRAZIL

    Nov 1, 2008, 00:00

  • PHC11 THE BURDEN OF ADHESIOLYSIS DURING LAPAROSCOPIC GYNECOLOGICAL SURGERY

    Nov 1, 2008, 00:00

  • PCN24 PEGYLATED LIPOSOMAL DOXORUBICIN IN COMBINATION WITH BORTEZOMIB FOR THE TREATMENT OF RELAPSED MULTIPLE MYELOMA-A COST-EFFECTIVENESS STUDY FOR SCOTLAND

    Nov 1, 2008, 00:00

  • PMH10 TOLERABILITY OF ONCE-DAILY EXTENDED RELEASE QUETIAPINE COMPARED TO QUETIAPINE IMMEDIATE RELEASE- A META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS IN SCHIZOPHRENIA

    Nov 1, 2008, 00:00

  • PSY52 QUALITY OF LIFE IN RUSSIAN PATIENTS WITH HEREDITARY COAGULOPATHIES. INTERMEDIATE RESULTS

    Nov 1, 2008, 00:00

  • PMH50 THE ROLE OF PRE-TREATMENT EXPECTANCY ON THE OUTCOME OF PRIMARY CARE TREATMENTS FOR DEPRESSION

    Nov 1, 2008, 00:00

  • PSS42 PSORIASIS AND THERMAL THERAPY- EVALUATION OF MEDICAL SERVICE

    Nov 1, 2008, 00:00

  • PMS42 COST-UTILITY EVALUATION OF THE TREATMENT OF PATIENTS WITH OSTEOARTHRITIS WITH IN SAPONIFICATES OF AVOCADO AND SOY (PIASCLEDINE )

    Nov 1, 2008, 00:00

  • PIH1 CHANGES IN PELVIC FLOOR MUSCLE STRENGTH, ITS DURATION AND ITS RELAXATION ABILITY DURING PREGNANCY

    Nov 1, 2008, 00:00

  • PIH23 MEDICATION COSTS IN ELDERLY PATIENTS

    Nov 1, 2008, 00:00

  • PHC2 IMPACT OF LOCAL HAEMOSTATIC AGENTS IN ABDOMINAL SURGERY ON HOSPITAL BUDGET

    Nov 1, 2008, 00:00

  • MO1 ADVANTAGES AND DISADVANTAGES OF MARKOV MODELS VERSUS DISCRETE EVENT MODELS FOR SIMULATING PATIENT FLOWS

    Nov 1, 2008, 00:00

  • PIN30 COST-EFFECTIVENESS ANALYSIS OF DROTRECOGIN ALFA (ACTIVATED; DAA) AS A TREATMENT FOR SEVERE SEPSIS WITH MULTIPLE ORGAN FAILURE (MOF) IN POLAND

    Nov 1, 2008, 00:00

  • PCN12 BUDGETARY IMPACT OF XELOX IN COLORECTAL CANCER IN ITALY

    Nov 1, 2008, 00:00

  • PCASE4 BRIDGING THE GAP OF EVIDENCE AND COSTEFFECTIVENESS- THE PRAGMATIC APPROACH USING ECONOMIC MODELLING TO ASSESS THE COSTEFFECTIVENESS FOR ASSISTIVE TECHNOLOGIES (AT) IN THE UK-BOTH PRE-AND POSTMARKETED

    Nov 1, 2008, 00:00

  • PIH22 PRICE-ELASTICITY OF DEMAND FOR INFERTILITY SERVICES IN GERMANY

    Nov 1, 2008, 00:00

  • PMS49 HEALTH-RELATED QUALITY OF LIFE (HRQL) OF MODERATE TO SEVERE RHEUMATOID ARTHRITIS (RA) PATIENTS IN GREECE- PRELIMINARY RESULTS FROM THE HEOR STUDY

    Nov 1, 2008, 00:00

  • PHP33 INFLUENCE OF MORBIDITY ON THE USE OF RESOURCES IN PRIMARY CARE- RETROSPECTIVE APPLICATION OF ACG AT A SPANISH INTERREGIONAL LEVEL

    Nov 1, 2008, 00:00

  • PSY49 PATIENT-REPORTED OUTCOMES, HEALTH CARE RESOURCES UTILIZATION, WORK PRODUCTIVITY AND THEIR ASSOCIATED COSTS IN PATIENTS WITH NEUROPATHIC PAIN- A CASE CONTROL COMPARISON OF TREATMENT WITH PREGABALIN VERSUS GABAPENTIN IN ROUTINE MEDICAL ...

    Nov 1, 2008, 00:00

  • OR2 INCORPORATING DIFFUSION OF NEW MEDICINES IN A BUDGET IMPACT ANALYSIS

    Nov 1, 2008, 00:00

  • PMS56 FIBROMYALGIA MOLDOFSKY QUESTIONNAIRE (FMQ)- VALIDATION OF A TOOL TO AID DIAGNOSIS

    Nov 1, 2008, 00:00

  • PCV22 TOLERABILITY OF ROSUVASTATIN 40 MG COMPARED TO 20 MG IN THE TREATMENT OF HYPERCHOLESTEROLAEMIA- EVIDENCE FROM RANDOMISED CONTROLLED TRIALS

    Nov 1, 2008, 00:00

  • PND27 UTILIZATION PATTERNS OF ANTIEPILEPTIC DRUGS- AN ITALIAN PRESCRIPTION DATABASE ANALYSIS

    Nov 1, 2008, 00:00

  • PIN35 HEALTH ECONOMIC ASSESSMENT OF A PRE-PANDEMIC INFLUENZA VACCINE FOR GERMANY

    Nov 1, 2008, 00:00

  • PMH39 RELATIONSHIP BETWEEN CLINICAL OUTCOMES AND PATIENTS REPORTED OUTCOMES IN SCHIZOPHRENIA- THE CONTRIBUTION OF THE EQ-5D

    Nov 1, 2008, 00:00

  • PMC9 DISCOUNTING COSTS AND BENEFITS OF HEALTH CARE PROGRAMMES- PROBLEMS OF THE SOCIAL TIME PREFERENCE APPROACH

    Nov 1, 2008, 00:00

  • PCV75 THE IMPACT OF POSTPRANDIAL PEAKS ON CARDIOVASCULAR COMPLICATIONS BEYONDTHE HBA1C LEVEL-A HEALTH ECONOMIC ASSESSMENT

    Nov 1, 2008, 00:00

  • OR3 ADJUSTING ICERS FOR FUTURE UNRELATED MEDICAL COSTS- DEVELOPMENT AND APPLICATION OF A TOOLKIT

    Nov 1, 2008, 00:00

  • PIN51 EVALUATION OF SEPSIS MANAGEMENT AND OUTCOMES AT A LARGE INNER-CITY ACADEMIC MEDICAL CENTER IN THE SURVIVING SEPSIS CAMPAIGN ERA

    Nov 1, 2008, 00:00

  • HT1 A SYSTEMATIC FRAMEWORK FOR COMPARING METHODS, PROCEDURES, AND IMPACT ACROSS HTA AGENCIES

    Nov 1, 2008, 00:00

  • PMH53 PREDICTIVE FACTORS OF RECURRENCE AND BIPOLAR DISORDER MANAGEMENT IN SPAIN- A PROSPECTIVE COHORT STUDY BASELINE ASSESSMENT

    Nov 1, 2008, 00:00

  • MO4 TRANSFERABILITY OF MODEL-BASED ECONOMIC EVALUATIONS- THE CASE OF TRASTUZUMAB FOR THE ADJUVANT TREATMENT OF HER2-POSITIVE EARLY BREAST CANCER IN THE NETHERLANDS

    Nov 1, 2008, 00:00

  • PMC13 ESTIMATING COST-OF-ILLNESS USING GENERALIZED LINEAR MODELS- AN ALTERNATIVE TO THE SMEARING APPROACH

    Nov 1, 2008, 00:00

  • PMC15 IN OR OUT? EMPIRICAL EVIDENCE ON INCOME LOSSES IN HEALTH STATE VALUATIONS AND IMPLICATIONS FOR ECONOMIC EVALUATIONS

    Nov 1, 2008, 00:00

  • PMC10 PREVALENT AND MULTIPLE FUTURE INCIDENT COHORTS IN COST-EFFECTIVENESS ANALYSIS

    Nov 1, 2008, 00:00

  • PMC45 WHAT PROPORTION OF DISEASES ARE QALYS AN IRRELEVANT MEASURE FOR?

    Nov 1, 2008, 00:00

  • PDB13 REMUBURSEMENT OF LONG-ACTING INSULIN ANALOGS IN POLAND- A BUDGT IMPACT ANALYSIS

    Nov 1, 2008, 00:00

  • HP3 TREATMENTS PATTERNS, RESOURCE USE AND RELATED HEALTH CARE COSTS IN DEPRESSED PATIENTS WITH CO-MORBID ANXIETY IN A LARGE US CLAIMS DATABASE

    Nov 1, 2008, 00:00

  • PSY55 PAIN MANAGEMENT IN THAILAND- IMPLICATION FOR BETTER PATIENT EDUCATION

    Nov 1, 2008, 00:00

  • DB4 COST OF MANAGING SEVERE HYPOGLYCAEMIA IN INSULIN-TREATED DIABETES IN THREE EUROPEAN COUNTRIES

    Nov 1, 2008, 00:00

  • PMH55 A COMPARISON OF PERSISTENCE AND HEALTH CARE COSTS RELATED TO DIFFERENT TREATMENT STRATEGIES AFTER INITIAL ESCITALOPRAM 10MG IN MAJOR DEPRESSIVE DISORDER

    Nov 1, 2008, 00:00

  • PCV74 COST-EFFECTIVENESS OF DABIGATRAN ETEXILATE FOR THE PRIMARY PREVENTION OF VENOUSTHROMBOEMBOLISM IN PATIENTS UNDERGOINGTOTAL HIP ORTOTAL KNEE REPLACEMENT SURGERY

    Nov 1, 2008, 00:00

  • PCN109 DEALING WITH QUALITY OF LIFE MISSING DATA IN A SINGLE ARM STUDY. COMPARISON OF MULTIPLE IMPUTATION METHODS

    Nov 1, 2008, 00:00

  • PND17 ONE-YEAR EXPENSES FOR THE PHARMACOLOGICAL MANAGEMENT OF EPILEPSY WITHIN OUTPATIENT SETTING OF MONTENEGRO- RATIONAL OR NOT?

    Nov 1, 2008, 00:00

  • IN2 MODELING LONG-TERM MORTALITY AND MORBIDITY IMPACT WITH ENTECAVIR TREATMENT IN CHB PATIENTS IN BELGIUM

    Nov 1, 2008, 00:00

  • PMH45 A COMPARISON OF PATIENT AND PHYSICIAN ATTITUDES TOWARDS THE GOALS FOR THE TREATMENT OF SCHIZOPHRENIA IN GERMANY

    Nov 1, 2008, 00:00

  • PDB30 INSTIGATE STUDY (INSULIN TITRATION; GAINING AN UNDERSTANDING OF THE BURDEN OF TYPE 2 DIABETES IN EUROPE)- HEALTH CARE RESOURCE UTILIZATION AND COSTS WITHIN THE FIRST 6 MONTHS OF INSULIN THERAPY-FRENCH DATA

    Nov 1, 2008, 00:00

  • PMS33 HEALTH ECONOMIC EVALUATION OF OUTPATIENT MANAGEMENT OF FIBROMYALGIA IN SPAIN

    Nov 1, 2008, 00:00

  • PCV93 FACTORS DETERMINING UTILITY MEASURED WITHTHE EQ-5D IN PATIENTS WITH A TRIAL FIBRILLATION

    Nov 1, 2008, 00:00

  • PMC24 SELF-ASSESSED HEALTH STATUS IN POLAND- EQ-5D FINDINGS FROM POLISH VALUATION STUDY

    Nov 1, 2008, 00:00

  • PSY61 INCREMENTAL SAVINGS ASSOCIATED WITH A DECREASE IN ANTIDEPRESSANT MEDICATIONS FOLLOWING BARIATRIC SURGERY IN WESTERN NEWYORK

    Nov 1, 2008, 00:00

  • PHP20 THE EFFECT OF THE INTRODUCTION OF HOSPITAL DAILY FEE ON THE NUMBER OF ADMISSIONS TO ACUTE CARE HOSPITALWARDS IN HUNGARY

    Nov 1, 2008, 00:00

  • PSY8 BUDGET IMPACT ANALYSIS OF DEFERASIROX FOR THE TREATMENT OF CHRONIC IRON OVERLOAD IN PATIENTS WITH BETATHALASSAEMIA IN VENETO REGION, ITALY

    Nov 1, 2008, 00:00

  • PRS7 THE TREATMENT OF MODERATE TO SEVERE PERSISTENT ASTHMA IN SELECTED AUTONOMOUS COMMUNITIES IN SPAIN- AN ECOMIC MODELTO ESTIMATE BUDGET IMPACT CONSEQUENCES OF INTRODUCING BECLOMETHASONE/FORMOTEROL

    Nov 1, 2008, 00:00

  • PCN75 AN UPDATED GEOGRAPHIC SUBPOPULATION ANALYSIS OF HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC) ENROLLED IN A PHASE III TRIAL OF SUNITINIB VERSUS INTERFERON-ALFA

    Nov 1, 2008, 00:00

  • PCV30 COST-EFFECTIVENESS ANALYSIS OF ENDOVASCULAR ANEURYSM REPAIR (EVAR) FOR ABDOMINAL AORTIC ANEURYSM (AAA) IN SPAIN

    Nov 1, 2008, 00:00

  • PIN20 COST-EFFECTIVENESS OF SURGICAL INTERVENTION FOR THERAPY-INDUCED FACIAL LIPOATROPHY IN HIV-INFECTED PATIENTS

    Nov 1, 2008, 00:00

  • PCN111 A STRUCTURED REVIEW OF STUDIES ON HEALTH-RELATED QUALITY OF LIFE IN KIDNEY CANCER, HEPATOCELLULAR CARCINOMA AND LEUKEMIA

    Nov 1, 2008, 00:00

  • PDB53 VALIDATION OF THE HUMAN GROWTH HORMONE PREFERENCE AND SATISFACTION QUESTIONNAIRE (HGH-PSQ)

    Nov 1, 2008, 00:00

  • PCN4 EFFICACY OF OPIOIDS IN THE TREATMENT OF BREAKTHROUGH CANCER PAIN- A BAYESIAN MIXED TREATMENT COMPARISON

    Nov 1, 2008, 00:00

  • PMC53 IS UTILITY A LINEAR FUNCTION OF LIFETIME?

    Nov 1, 2008, 00:00

  • PMC60 CONSISTENTLY ESTIMATING RISK DIFFERENCE IN A JURISDICTION OF INTEREST- ODDS SOLUTION TO RELATIVE RISK FALLACIES

    Nov 1, 2008, 00:00

  • PSS12 SENSITIVE SKINS IN PORTUGAL- AN EPIDEMIOLOGICAL APPROACH

    Nov 1, 2008, 00:00

  • PSS33 THE COST OF UVEITIS TREATMENT IN FRANCE- A ONE-YEAR RETROSPECTIVE ANALYSIS

    Nov 1, 2008, 00:00

  • PG130 A EUROPEAN CROSS-SECTIONAL STUDY TO EVALUATE SYMPTOM BURDEN AND CLINICAL MANAGEMENT OF GASTROESOPHAGEAL REFLUX DISEASE (RANGE-GREECE)

    Nov 1, 2008, 00:00

  • PDB7 LONGTERM HEALTH OUTCOMES IN NEWLY DIAGNOSED TREATMENT NA VE TYPE 2 DIABETES PATIENTS INITIATED WITH BIPHASIC INSULIN ASPART IN CHINA- DATA FROM THE IMPROVE STUDY

    Nov 1, 2008, 00:00

  • PCV76 THE KOREAN INDIVIDUAL-MICROSIMULATION MODEL FOR CARDIOVASCULAR HEALTH INTERVENTIONS (KIMCHI)

    Nov 1, 2008, 00:00

  • PRS2 RELATIVE EFFECTIVENESS OF INHALED CORTICOSTEROIDS AND LEUKOTRIENE-RECEPTOR ANTAGONISTS TO PREVENT MODERATE-TO-SEVERE EXACERBATIONS AMONG ASTHMATIC CHILDREN

    Nov 1, 2008, 00:00

  • MH4 HEALTH SERVICE EXPENDITURES FOR CHILDREN AND ADOLESCENTS WITH AND WITHOUT ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) IN GERMANY-IMPACT OF COEXISTING CONDITIONS

    Nov 1, 2008, 00:00

  • PG121 REDUCTION OF WORK PRODUCTIVITY ASSOCIATED WITH GASTROESOPHAGEAL REFLUX DISEASE (GERD) AND RELATED COSTS

    Nov 1, 2008, 00:00

  • EE1 DISCRETE CHOICE EXPERIMENTS OF COMPLEX HEALTH CARE DECISIONS- DOES HIERARCHICAL INFORMATION INTEGRATION OFFER A SOLUTION?

    Nov 1, 2008, 00:00

  • PND11 EPILEPSY COST OF ILLNESS IN THE U.S. PRIVATELY INSURED

    Nov 1, 2008, 00:00

  • PCV5 A REALWORLD COMPARISON OF COMBINED LIPID TARGET ATTAINMENT BETWEEN COMBINATION NIACIN EXTENDED-RELEASEEZETIMIBE

    Nov 1, 2008, 00:00

  • PIN48 VALIDATION OF THE ACTIVITY IMPAIRMENT ASSESSMENT IN PATIENTS WITH ACUTE BACTERIAL SINUSITIS

    Nov 1, 2008, 00:00

  • PHP47 ASSOCIATION BETWEEN HEALTH-RELATED QUALITY OF LIFE AND HEALTH SERVICE UTILIZATION AMONG PRIMARY CARE PATIENTS

    Nov 1, 2008, 00:00

  • PCN18 AN EVALUATION OF THE COST SAVINGS GENERATED WITH THE USE OF AN INTRA-OPERATIVE ASSAY FOR THE DETECTION OF METASTASES IN THE SENTINEL LYMPH NODES OF PATIENTS WITH BREAST CANCER

    Nov 1, 2008, 00:00

  • PSS5 IMPACT OF COMPLIANCE ON INTRA-OCULAR PRESSURE (IOP) CONTROL IN GLAUCOMA PATIENTS

    Nov 1, 2008, 00:00

  • PDB10 COMPREHENSIVE LIPID PROFILE AMONGTYPE 2 DIABETES MELLITUS (T2DM) POPULATION IN SPAIN. RECAP-DM SPANISH COHORT STUDY

    Nov 1, 2008, 00:00

  • PCV46 COST-EFFECTIVENESS OF CLOPIDOGREL IN MYOCARDIAL INFARCTION WITH ST-SEGMENT ELEVATION- A SPANISH MODEL BASED ON THE CLARITY AND COMMITTRIALS

    Nov 1, 2008, 00:00

  • PDB51 UNDERSTANDING AND ASSESSING THE IMPACT OF DIABETES TREATMENT ACROSS MEDICATION DELIVERY SYSTEMS

    Nov 1, 2008, 00:00

  • PUK17 ESTIMATING THE QUALITY OF LIFE IMPACTS OF TOLTERODINE AND TAMSULOSIN TREATMENT IN MEN WITH LOWER URINARY TRACT SYMPTOMS AND OVERACTIVE BLADDER

    Nov 1, 2008, 00:00

  • PIN49 INTERNATIONAL DEVELOPEMENT OF A NEW HEALTH-RELATED QUALITY OF LIFE QUESTIONNAIRE SPECIFIC TO HIV/AIDS-PROQOL HIV STUDY

    Nov 1, 2008, 00:00

  • PDB18 A COMPARISON OF COSTS AMONG PATIENTS WITH TYPE 2 DIABETESWHO INITIATED THERAPY WITH EXENATIDE OR SITAGLIPTIN

    Nov 1, 2008, 00:00

  • PHP23 CHARACTERISTICS OF UTILIZATION OF PRIMARY CARE OF GENERAL PRACTITIONERS IN COUNTY BARANYA IN HUNGARY

    Nov 1, 2008, 00:00

  • PCN78 QUALITY OF LIFE (QOL) IN PATIENTS WITH METASTATIC BREAST CANCER (MBC) IN TREATMENT WITH PLACITAXEL WITH/WITHOUT BEVACIZUMAB, RELATED WITH TREATMENT RESPONSE (REMISSION AND PROGRESSION)

    Nov 1, 2008, 00:00

  • PRS28 HAS ASTHMA CONTROL IMPROVED SINCE AIRE? RESULTS OF A SURVEY IN 5 EUROPEAN COUNTRIES

    Nov 1, 2008, 00:00

  • PCN72 THE IMPACT OF INITIAL TREATMENT CHOICE AND DISEASE PROGRESSION ON THE ECONOMIC BURDEN OF PATIENTS AND THEIR CAREGIVERS-A LONGITUDINAL STUDY OF STAGE IV NON-SMALL CELL LUNG CANCER (NSCLC)

    Nov 1, 2008, 00:00

  • PND7 COST-EFFECTIVENESS OF A LIDOCAINE PLASTER RELATIVE TO PREGABALIN IN THE TREATMENT OF POST-HERPETIC NEURALGIA IN THE NETHERLANDS

    Nov 1, 2008, 00:00

  • PMH9 TOLERABILITY OF A TYPICAL ANTIPSYCHOTICS IN THE TREATMENT OF SCHIZOPHRENIA AND BIPOLAR DISORDER- A SYSTEMATIC REVIEW OF RANDOMISED CONTROLLED TRIALS

    Nov 1, 2008, 00:00

  • PCN30 COST-EFFECTIVENESS OF APREPITANT IN PATINENTS RECEIVING ANTIEMETIC PROPHYLAXIS FOR HIGHLY EMETOGENIC CHEMOTHERAPY IN HUNGARY

    Nov 1, 2008, 00:00

  • PCN96 ASSOCIATION BETWEEN RESPONDENT- AND PRACTICE-RELATED CHARACTERISTICS AND RADIATION ONCOLOGY STAFF-REPORTED BURDEN ON MUCOSITIS MANAGEMENT FOR HEAD AND NECK CANCER (HNC) PATIENTS

    Nov 1, 2008, 00:00

  • PMS14 NEW STRATEGIES IN THE TREATMENT OF RHEUMATOID ARTHRITIS PATIENTS IN ITALY- A BUDGET IMPACT ANALYSIS

    Nov 1, 2008, 00:00

  • PRS35 CHALLENGING ASTHMA MANAGEMENT WITH THE USE OF LABA/ICS COMBINATION VIA ATURBUHALER DEVICE, BOTH FOR MAINTENANCE AS WELL AS RELIEF, AND IT WELL-BEING IN GREECE

    Nov 1, 2008, 00:00

  • PMH48 TELEPHONE HOTLINE AS AN ADJUNCT TO CONTINUING CARE FOR ADOLESCENTS TREATED FOR PSYCHOACTIVE SUBSTANCE USE DISORDER

    Nov 1, 2008, 00:00

  • PRS33 FACTORS AFFECTING QUALITY OF LIFE OF ASTHMATIC AND COPD PATIENTS

    Nov 1, 2008, 00:00

  • PMH11 DRUG-RELATED PUBLIC EXPENDITURE IN EUROPE- THE BUDGET IMPACT OF ILLEGAL DRUGS

    Nov 1, 2008, 00:00

  • HP1 ANALYSIS OF THE ORPHAN DRUG DESIGNATIONS AND APPROVALS GRANTED BY THE EMEA AND THE USA FDA BETWEEN 2000 AND 2007

    Nov 1, 2008, 00:00

  • PMH21 COST-EFFECTIVENESS-ANALYSIS OF RISPERIDONE LONG-ACTING INJECTION IN SCHIZOPHRENIA- 12 MONTH DATA FROM CZECH REPUBLIC

    Nov 1, 2008, 00:00

  • PND22 ELICITING UTILITY SCORES FOR HEALTH STATES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME

    Nov 1, 2008, 00:00

  • PCN28 COST-UTILITY ANALYSIS IN A SPANISH SETTING OF ADJUVANT THERAPY WITH TRASTUZUMAB (HERCEPTIN) IN PATIENTS WITH HER-2 POSITIVE BREAST CANCER

    Nov 1, 2008, 00:00

  • PMH8 TOLERABILITY OF ONCE-DAILY EXTENDED RELEASE QUETIAPINE COMPARED TO QUETIAPINE IMMEDIATE RELEASE IN THE TREATMENT OF ACUTE BIPOLAR DISORDER- AN ADJUSTED INDIRECT COMPARISON

    Nov 1, 2008, 00:00

  • PIN40 MANAGEMENT AND COST ASSOCIATED WITH NON-PERMANENT CATHETER-RELATED BACTERAEMIA CAUSED BY MICROORGANISMS GRAM-POSITIVES IN SPANISH HOSPITALS SETTINGS

    Nov 1, 2008, 00:00

  • PMH36 WHAT DO PATIENTS WITH SCHIZOPHRENIAWANT OUT OF THEIR MEDICATION? IDENTIFYING PATIENT REPORTED 'PROCESSES' IN MENTAL HEALTH

    Nov 1, 2008, 00:00

  • PSS31 ACUTE OTITIS MEDIA- A MAJOR SOURCE OF PRODUCTIVITY LOSS

    Nov 1, 2008, 00:00

  • PMS12 THE ROLE OF DIFFERENT CO-MORBIDITIES IN THE EVALUATION OF CORRELATION BETWEEN CERTAIN RISK FACTORS AND THE ONE YEAR MORTALITY FOLLOWING FEMORAL NECK FRACTURE

    Nov 1, 2008, 00:00

  • EE4 CAREER INTERRUPTIONS AND SICK LEAVES AMONG FIBROMYALGIA PATIENTS

    Nov 1, 2008, 00:00

  • PCV99 A CROSS-NATIONAL COMPARISON ON PRICES OF PHARMACEUTICAL PRODUCT

    Nov 1, 2008, 00:00

  • PMC2 HASTHE QUALITY OF RANDOMISED CONTROLLED TRIALS INCREASED WITH TIME- AN ANALYSIS OF DATA FROM 5 SYSTEMATIC REVIEWS?

    Nov 1, 2008, 00:00

  • PCN107 NEW OPPORTUNITIES FOR DRUG OUTCOMES RESEARCH IN CANCER PATIENTS- VALIDATION OF THE LINKAGE OF THE EINDHOVEN CANCER REGISTRY AND THE PHARMO RECORD LINKAGE SYSTEM

    Nov 1, 2008, 00:00

  • PCV101 PROSPECTIVE STUDY TO EVALUATE THE IMPACT OF A DISEASE EDUCATION PROGRAM OF CARDIOVASCULAR RISK CONTROL IN HYPERTENSION

    Nov 1, 2008, 00:00

  • PG120 ASSESSING THE COST AND EFFECTIVENESS OF TERLIPRESSIN COMPARED WITH SOMATOSTATIN FOR THE TREATMENT OF BLEEDING OESOPHAGEAL VARICES IN SPAIN

    Nov 1, 2008, 00:00

  • PHP21 THE EFFECT OF THE INTRODUCTION OF VISIT FEE ON THE NUMBER OF PATIENT-VISITS TO OUTPATIENT CARE DEPARTMENTS IN HUNGARY

    Nov 1, 2008, 00:00

  • PMS39 COST-UTILITY OF ABATACEPT IN RHEUMATOID ARTHRITIS PATIENTS WITH AN INSUFFICIENT RESPONSE OR INTOLERANCE TO ANTI-TNF THERAPY IN ITALY- A PROBABILISTIC SENSITIVITY ANALYSIS

    Nov 1, 2008, 00:00

  • PMS6 PREVALENCE OF FIBROMYALGIA IN FRANCE

    Nov 1, 2008, 00:00

  • Author Index

    Nov 1, 2008, 00:00

  • PMH18 THE COST-EFFECTIVENESS OF PALIPERIDONE ER IN LONG-TERM TREATMENT OF SCHIZOPHRENIA IN TURKEY

    Nov 1, 2008, 00:00

  • EE5 COST-EFFECTIVENESS OF ATORVASTATIN IN TYPE 2 DIABETES PATIENTS- A PHARMACO-ECONOMIC ANALYSIS OF THE COLLABORATIVE ATORVASTATIN DIABETES STUDY (CARDS) IN THE BELGIAN POPULATION

    Nov 1, 2008, 00:00

  • PDB28 DIABETES MELLITUS BURDEN AND RELATIONSHIP WIHTHE DEGREE OF PATIENTxS GLYCEMIC CONTROL

    Nov 1, 2008, 00:00

  • MH8 DIRECT COST OF TREATING PATIENTS WITH SCHIZOPHRENIA IN GREECE- REAL-WORLD DATA FROM THE ELECTRONIC SCHIZOPHRENIA TREATMENT ADHERENCE REGISTRY (E-STAR)

    Nov 1, 2008, 00:00

  • PCN17 ESTIMATING THE COST SAVINGS FROM THE INTRODUCTION OF KRAS TESTING IN THE MANAGEMENT OF METASTATIC COLORECTAL CANCER (MCRC) PATIENTS RECEIVING PANITUMUMAB IN GREECE

    Nov 1, 2008, 00:00

  • PDB52 A SELF-MANAGEMENT PROFILE FOR PATIENTS WITH TYPE-2 DIABETES

    Nov 1, 2008, 00:00

  • PSS57 RETROSPECTIVE CHART REVIEW TO ASSESS IMPLEMENTATION OF NICE GUIDANCE ON THE USE OF BIOLOGICAL THERAPIES IN PATIENTS WITH CHRONIC PLAQUE PSORIASIS

    Nov 1, 2008, 00:00

  • PMH1 PREVALENCE OF TIC DISORDERS AND COEXISTENCE WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) IN A GERMAN COMMUNITY SAMPLE

    Nov 1, 2008, 00:00

  • PHP53 EXPANDINGTHE PHYSICIAN QUALITY REPORTING INITIATIVE (PQRI)- MEASURES GROUPS AND REGISTRY-BASED REPORTING

    Nov 1, 2008, 00:00

  • PMH41 SAD BLUE DEPRESSED DAYS, HEALTH-RELATED QUALITY OF LIFE, AND HEALTH BEHAVIORS AMONGWOMEN IN A UNIVERSITY COMMUNITY

    Nov 1, 2008, 00:00

  • MS2 LINGUISTIC VALIDATION OF SIX QUALITY OF LIFE QUESTIONNAIRES FOR FIBROMYALGIA PATIENTS IN TWELVE LANGUAGES

    Nov 1, 2008, 00:00

  • PCN11 BUDGET IMPACT ANALYSIS OF DIFFERENT TREATMENT PROTOCOLS FORTRASTUZUMAB

    Nov 1, 2008, 00:00

  • PCV98 MODELLING THE EFFECT OF DIAGNOSTIC STRATEGIES IN PATIENTS WITH SUSPECTED CORONARY ARTERY DISEASE (CAD) ON CAPACITY AND PRODUCTIVITY OF CORONARY DIAGNOSTIC FACILITIES IN THE UNITED KINGDOM

    Nov 1, 2008, 00:00

  • PSS6 EFFECTIVENESS OF MOXIFLOXACIN IN THE TREATMENT OF BACTERIAL CONJUNCTIVITIS IN ADULTS

    Nov 1, 2008, 00:00

  • PMS23 INITIAL COMBINATION THERAPY WITH INFLIXIMAB VERSUS SEQUENTIAL DMARD MONOTHERAPY- A COST-EFFECTIVENESS MODEL BASED ON THE BEST STUDY

    Nov 1, 2008, 00:00

  • PUK22 FACTORS ASSOCIATED WITH PERCEIVED SATISFACTION IN HEMODYALISIS PATIENTS

    Nov 1, 2008, 00:00

  • PHP38 COST-EFFECTIVENESS OF PREVENTION- OPPORTUNITIES FOR PUBLIC HEALTH POLICY IN THE NETHERLANDS?

    Nov 1, 2008, 00:00

  • PCN82 TESTING THE MEASUREMENT EQUIVALENCE OF PAPER AND INTERACTIVE VOICE RESPONSE (IVR) VERSIONS OF THE EQ-5D

    Nov 1, 2008, 00:00

  • PCN34 PHARMAECONOMIC EVALUATION OF THE USE OF ERLOTINIB IN NON-SMALL CELLS LUNG CANCER (NSCLC) WITH FAILURE TO PREVIOUS CHEMOTHERAPY

    Nov 1, 2008, 00:00

  • PCV29 ESTIMATING THE BUDGET IMPACT OF DABIGATRAN ETEXILATE IN THE PRIMARY PREVENTION OF VENOUS THROMBOEMBOLISM FOLLOWINGTOTAL HIP OR KNEE REPLACEMENT SURGERY- AN INTERACTIVE MODEL FOR LOCAL HEALTH ECONOMIES IN THE UK

    Nov 1, 2008, 00:00

  • PMH24 DIRECT COSTS OF UNTREATED COMORBID-INSOMNIA IN AN ADULT DEPRESSED MANAGED CARE POPULATION

    Nov 1, 2008, 00:00

  • PMC29 PATIENT REPORTED OUTCOMES RESEARCH IN A REAL TIME PRACTICE NETWORK

    Nov 1, 2008, 00:00

  • PSY15 ECONOMIC IMPLICATIONS OF IRON CHELATION IN PATIENTS WITH REFRACTORY ANEMIA RELATED TO MYELODYSPLASTIC SYNDROME

    Nov 1, 2008, 00:00

  • PHP18 COMPARISON OF COST/QALY RATIO IN DIAGNOSTIC AND THERAPEUTIC DEVICES OR DRUGS

    Nov 1, 2008, 00:00

  • CV1 WHAT IS THE CLINICAL BENEFIT OF PREVENTING NON-FATAL MYOCARDIAL INFARCTIONS?

    Nov 1, 2008, 00:00

  • PMC55 THE C-STATISTIC AND THE EFFICIENCY OF THE PROPENSITY SCORES MODEL- EVIDENCE FROM SIMULATED DATA

    Nov 1, 2008, 00:00

  • PUK9 COST OF OVERACTIVE BLADDER IN THE UNITED STATES

    Nov 1, 2008, 00:00

  • PIH14 COSTS AND OUTCOMES ASSOCIATED WITH IN VITRO FERTILISATION (IVF) OR INTRACYTOPLASMIC SPERM INJECTION (ICSI) USING RECOMBINANT FOLLICLE STIMULATING HORMONE (RFSH)

    Nov 1, 2008, 00:00

  • PND24 CANTHE CHQ-PF50 BE USED TO MONITOR CHANGES IN BEHAVIORAL AND EMOTIONAL FUNCTIONING IN CHILDREN TREATED FOR EPILEPSY?

    Nov 1, 2008, 00:00

  • PCV13 ATTAINMENT OF MULTIPLE RECOMMENDED LIPID LEVELS FOLLOWING LIPID MODIFYING TREATMENT IN HIGH RISK PATIENTS. PRIMULA STUDY, SPAIN

    Nov 1, 2008, 00:00

  • PND9 WITHIN-TRIAL COST EFFECTIVENESS ANALYSIS OF ARIPIPRAZOLE COMPARED TO STANDARD-OF-CARE IN THE SCHIZOPHRENIA TRIAL OF ARIPIPRAZOLE (STAR)

    Nov 1, 2008, 00:00

  • PMS40 COST-EFFECTIVENESS ANALYSIS OF ANNUAL DOSE OF ZOLEDRONIC ACID VERSUS ORALLY ADMINISTERED BISPHOSPHONATES IN PREVENTION OF OSTEOPOROTIC FRACTURES IN CZECH POST-MENOPAUSALWOMEN

    Nov 1, 2008, 00:00

  • PMC31 VALUING EQ-5D WITH TIME TRADE-OFF FOR THE POLISH POPULATION

    Nov 1, 2008, 00:00

  • PCV50 COST-EFFECTIVENESS OF RULING OUT DEEPVENOUS THROMBOSIS IN PRIMARY CARE VERSUS CARE AS USUAL

    Nov 1, 2008, 00:00

  • PCV121 LIPID MANAGEMENT OF HIGH RISK PATIENTS IN THE OUTPATIENT SETTING IN GERMANY- RESULTS OF DYSIS-GERMANY

    Nov 1, 2008, 00:00

  • PRS40 DECISION-MAKING IN HEALTH CARE USING COST-EFFECTIVENESS EVIDENCE-SMOKING CESSATION COMPARED TO TREATMENT OF SMOKING-RELATED DISEASES

    Nov 1, 2008, 00:00

  • PG114 A HYPOTHETICAL ROAD MAPTO REDUCE ACID RELATED DISEASES COSTS MANAGEMENT

    Nov 1, 2008, 00:00

  • PSS29 SOCIETAL COSTS OF SEVERE CHRONIC HAND ECZEMA (CHE) IN GERMANY

    Nov 1, 2008, 00:00

  • PDB15 COMPARATIVE COST-UTILITY ANALYSIS OF LONG-ACTING INSULIN ANALOGUE (INSULIN DETEMIR) AND NPH INSULIN FOR THE TREATMENT OF TYPE 1 AND TYPE 2 DIABETES AND THE BUDGET IMPACT ANALYSIS OF INSULIN ANALOGUE REIMBURSEMENT IN POLAND

    Nov 1, 2008, 00:00

  • PMH29 HEALTH CARE RESOURCE UTILIZATION AND COSTS OF MILD, MODERATE, AND SEVERE DEPRESSION IN THE UNITED STATES

    Nov 1, 2008, 00:00

  • PMC23 WHAT IS POLITICIANS WILLINGNESS TO PAY (WTP) FOR FUTURE HEALTH BENEFIT BASED ON 15D, EQ-5D AND LIFE-YEARS? A CONTINGENTVALUATION (CV) AMONG 8 DISEASES WITH THE TOTAL OF 1092 CASES

    Nov 1, 2008, 00:00

  • PSS59 IMPACT OF HEALTH CARE REGULATION ON PROSTAGLANDIN ANALOGUE PRESCRIBING IN 5 EUROPEAN COUNTRIES

    Nov 1, 2008, 00:00

  • PIN8 PATIENT FLOW PATHWAY FOR PATIENTS ADMITTED TO CRITICAL CARE UNITS WITH A SEVERE BACTERIAL INFECTION IN ENGLAND

    Nov 1, 2008, 00:00

  • PCN5 TREATMENT EFFECT OF RITUXIMAB, FLUDARABINE AND CYCLOPHOSPHAMIDE (R-FC) VERSUS FC IN CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL) IN AN OBSERVATIONAL SETTING- AN INVESTIGATION OF PROGNOSTIC FACTORS AND LIFETIME HEALTH OUTCOMES

    Nov 1, 2008, 00:00

  • PSY51 PATIENT-REPORTED OUTCOMES (PRO) IN SUBJECTS WITH REFRACTORY PAIN ASSOCIATED TO LOW BACK PAIN- A POST-HOC ANALYSIS OF THE EFFECT OF PREGABALIN IN A 12-WEEK PROSPECTIVE STUDY UNDER ROUTINE MEDICAL PRACTICE CONDITIONS

    Nov 1, 2008, 00:00

  • PRS12 COST-EFFECTIVENESS ANALYSIS OF SYMBICORT SMART VERSUS FIXED COMBINATION TREATMENTS IN FINLAND

    Nov 1, 2008, 00:00

  • PHP2 CONSUMERS PERCEPTIONS OF DRUG EFFECTIVENESS AND PRICES IN GREECE

    Nov 1, 2008, 00:00

  • PHP15 DETERMINANTS OF PHARMACEUTICAL CONSUMPTION IN A GENERAL POPULATION

    Nov 1, 2008, 00:00

  • PSY58 RETROSPECTIVE ANALYSIS OF FACTORVIII UTILIZATION IN MATCHED HEMOPHILIA A PATIENTS TREATED WITH EITHER RECOMBINANT B DOMAIN-DELETED OR FULL-LENGTH FACTOR VIII

    Nov 1, 2008, 00:00

  • PG111 A COST-EFFICACY ANALYSIS MODEL FOR PHYSICIAN ADMINISTERED ANTI-TUMOR NECROSIS FACTOR AGENTS IN CROHNS DISEASE

    Nov 1, 2008, 00:00

  • PCV73 COST-EFFECTVENESS OF ENDOVASCULAR ANEURYSM REPAIR VERSUS OPEN SURGICAL REPAIR- ACUTE INFRARENAL ABDOMINAL AORTIC ANEURYSM IN AN EMERGENCY SETTING

    Nov 1, 2008, 00:00

  • PIH17 TURKISH CULTURAL ADAPTATION AND VALIDATION OF THE MENOPAUSE-SPECIFIC QUALITY OF LIFE QUESTIONNAIRE

    Nov 1, 2008, 00:00

  • PHP3 INNOVATIVE HEALTHTECHNOLOGIES IN THE 'ANTI-AGING-MEDICINE' FIELD- RESULTS FROM A SYSTEMATIC HORIZON SCANNING

    Nov 1, 2008, 00:00

  • PG18 A COST-EFFECTIVENESS EVALUATION-RETREATMENT WITH PEGYLATED INTERFERON ALFA 2B PLUS RIBAVIRIN IN HEPATITIS C PATIENTSWHO HAVE PREVIOUSLY RECEIVED INTERFERON-BASED THERAPY AND FAILED TO ATTAIN A SUSTAINED VIROLOGICAL RESPONSE

    Nov 1, 2008, 00:00

  • PIH2 ONE DAY NATIONAL SURVEY ON PREVALENCE OF MALE SEXUAL DYSFUNCTION, AMONG MEN CONSULTING UROLOGISTS

    Nov 1, 2008, 00:00

  • PIN13 ECONOMIC ANALYSIS OF MICAFUNGIN VERSUS LIPOSOMAL AMPHOTERICIN B FOR TREATMENT OF CANDIDAEMIA AND INVASIVE CANDIDIASIS IN ITALY

    Nov 1, 2008, 00:00

  • PSS56 PRESCRIPTION REFILLS AND HEALTH CARE COSTS ASSOCIATED WITH TOPICAL METRONIDAZOLE IN MEDICAID ENROLLED PATIENTS WITH ROSACEA

    Nov 1, 2008, 00:00

  • PCV123 THE CARDIOVASCULAR PREVENTION MODEL (CPM), A GENERICALLY APPLICABLE MODEL FOR UNDERTAKING COST-EFFECTIVENESS ANALYSES OF PREVENTIVE INTERVENTIONS

    Nov 1, 2008, 00:00

  • PG123 QUALITY OF LIFE (HEALTH-RELATED UTILITY) IN ADULTS WITH ULCERATIVE COLITIS IN REMISSION VS. MILD/MODERATE AND SEVERE RELAPSE- FINDINGS FROM THE PODIUM STUDY

    Nov 1, 2008, 00:00

  • PCV91 IMPACT OF CATHETER ABLATION VERSUS ANTIARRHYTHMIC DRUGS ON QUALITY OF LIFE IN PATIENTS WITH A TRIAL FIBRILLATION

    Nov 1, 2008, 00:00

  • PSY16 THE ECONOMIC IMPACT OF DIFFERENT STRATEGIES OF MANAGING RARE DISEASES WITH HIGH TREATMENT COSTS- THE CASE OF USING ACTIVATED RECOMBINANT FACTORVII IN SEVERE BLEEDS IN ACQUIRED HAEMOPHILIA PATIENTS

    Nov 1, 2008, 00:00

  • PRS39 GIVING-UP SMOKING- PREDICTIVE FACTORS OF SMOKING CESSATION AND ATTEMPTS TO STOP IN A FRENCH COHORT

    Nov 1, 2008, 00:00

  • PG135 PATIENT PREFERENCES FOR CROHNS DISEASE FLARE-UP THERAPY- A DISCRETE CHOICE EXPERIMENT

    Nov 1, 2008, 00:00

  • OR4 UTILITIES SHOULD NOT BE MULTIPLIED- EVIDENCE FROM THE PREFERENCE-BASED SCORES IN THE UNITED STATES

    Nov 1, 2008, 00:00

  • PCV15 CORONS STUDY- EXAMPLE OF STATINS IMPACT ON ALL CAUSE MORTALITY IN THE ELDERLY

    Nov 1, 2008, 00:00

  • QL12 FRENCH NORMATIVE REFERENCE DATA FOR THE QUALITY OF LIFE ASSESSMENT OF GROWTH HORMONE DEFICIENCY IN ADULTS (QOL-AGHDA) QUESTIONNAIRE

    Nov 1, 2008, 00:00

  • PMS38 COST-EFFECTIVENESS OF RITUXIMAB AS SECOND-LINE BIOLOGICAL TREATMENT COMPARED TO REGISTRY DATA

    Nov 1, 2008, 00:00

  • PUK21 CONTENTVALIDITY OF THE SUBJECTS HEALTH QUESTIONNAIRE, AND INTERNATIONAL CONSULTATION ON INCONTINENCE QUESTIONNAIRE-SHORT FORM IN PATIENTS WITH OAB

    Nov 1, 2008, 00:00

  • PSY24 MANAGEMENT OF HERPES ZOSTER (HZ) AND POST-HERPETIC NEURALGIA (PHN) IN BELGIUM- A COST OF ILLNESS STUDY

    Nov 1, 2008, 00:00

  • PUK10 ECONOMIC IMPACT OF A LOW-PROTEIN DIET AIMING TO DELAY THE HAEMODIALYSIS TREATMENT IN PATIENTS WITH CHRONIC-RENAL-FAILURE

    Nov 1, 2008, 00:00

  • PIN42 DIRECT MEDICAL COSTS AND PRODUCTIVITY LOSS ASSOCIATED WITH VENOUS LEG ULCER

    Nov 1, 2008, 00:00

  • PHC13 CHANGINGTHE SURGICALWOUND CLOSURE MANAGEMENT PATHWAY- TIME AND SUPPLIES WITH PRINEO VS. STANDARD OF CARE FOR ABDOMINOPLASTY SURGERY IN GERMANY

    Nov 1, 2008, 00:00

  • PMH31 A GPRD-BASED COMPARISON OF SECOND-LINE ANTIDEPRESSANT THERAPY WITH ESCITALOPRAM AND VENLAFAXINE

    Nov 1, 2008, 00:00

  • PCV77 COST EFFECTIVENESS OF HIGH DOSE ATORVASTATIN IN ACUTE CORONARY SYNDROME PATIENTS IN THE UK

    Nov 1, 2008, 00:00

  • PDB8 BURDEN OF DIABETES AND ASSOCIATED TREATMENT PATTERNS IN EUROPE- A COMPARISON OF SIX COUNTRIES

    Nov 1, 2008, 00:00

  • PG15 A BUDGET IMPACT ANALYSIS FOR DETERMINING THE COSTS OF INCREASED PANTOPRAZOL IV PRESCRIPTION FOR THE MANAGEMENT OF PEPTIC ULCER IN SPAIN

    Nov 1, 2008, 00:00

  • PIN21 ECONOMICAL EVALUATION OF ETRAVIRINE IN TREATMENT-EXPERIENCED HIV-1-INFECTED PATIENTS BASED ON DUET TRIALS

    Nov 1, 2008, 00:00

  • PMC1 COLLECTING REAL DATA FROM REAL PATIENTS

    Nov 1, 2008, 00:00

  • PDB42 COST-UTILITY OF INSULIN GLARGINE COMPARED TO PRE MIX IN TYPE 2 FROM PUBLIC PAYER PERSPECTIVE IN POLAND

    Nov 1, 2008, 00:00

  • PCV113 PATIENTS WITH ACUTE ST-ELEVATION MYOCARDIAL INFARCTION- WHOARE THE 'UNTREATED PATIENTS' IN HOSPITALS WITH CATH LAB?

    Nov 1, 2008, 00:00

  • PCV49 COST-EFFECTIVENESS OF ATORVASTATIN 80 MGVS GENERIC SIMVASTATIN 20 TO 40 MG IN SECONDARY PREVENTION IN SPAIN

    Nov 1, 2008, 00:00

  • PMS10 PREVALENCE OF FIBROMYALGIA IN SPAIN

    Nov 1, 2008, 00:00

  • PSS22 FINAL EVALUATION OF THE PERSISTENCE DEGREE OF PATIENTS IN FIRST-LINE MONOTHERAPY ANTIGLAUCOMATOUS TREATMENT IN SPAIN

    Nov 1, 2008, 00:00

  • MH1 HOW MUCH SHOULDWE BE PREPARED TO PAY FOR PSYCHOSOCIAL INTERVENTIONS FOR PATIENTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)?

    Nov 1, 2008, 00:00

  • CV3 PREDICTED OPTIMAL LIPID VALUE ATTAINMENT WITH THE CO-ADMINISTRATION OF FENOFIBRIC ACID AND A STATIN COMPARED TO STATIN MONOTHERAPY IN PATIENTS WITH MULTIPLE LIPID ABNORMALITIES

    Nov 1, 2008, 00:00

  • PMH52 PILOT SURVEY OF ADVERSE EVENT MANAGEMENT ASSOCIATED WITH ANTIPSYCHOTIC USE- THE NEGLECTED DIMENSION IN RESOURCE USE IMPLICATIONS (A UK PERSPECTIVE)

    Nov 1, 2008, 00:00

  • MO3 COMPARING METHODS OF DATA SYNTHESIS- UPDATING PARAMETERS OF AN EXISTING PROBABILISTIC COST-EFFECTIVENESS MODEL

    Nov 1, 2008, 00:00

  • PIN6 AN OBSERVATIONAL HEALTH ECONOMIC ANALYSIS OF THE COMBINED THERAPY WITH PEGINTERFERON ALPHA-2A (PEGASYS) AND RIBAVIRIN IN PATIENTS WITH CHRONIC C HEPATITIS (CHC) IN A REAL LIFE SETTING

    Nov 1, 2008, 00:00

  • PIN4 A MARKOV MODELTO ESTIMATE THE IMPACT ON MORBIDITY AND MORTALITY IN PATIENTS WITH CHRONIC HEPATITIS C (CHC) AND NORMALTRANSAMINASES (ALT-N) TREATED WITH PEGYLATED BITHERAPY

    Nov 1, 2008, 00:00

  • MD2 COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF ENDEVOR DRUG-ELUTING STENT COMPARED TO BARE-METAL STENTS AND CORONARY ARTERY BYPASS GRAFT SURGERY IN SPAIN

    Nov 1, 2008, 00:00

  • PSY14 COST-EFFECTIVENESS (CE) EVALUATION OF THE USE OF RITUXIMAB-CHOP VS. CHOP SCHEMES FOR THE TREATMENT OF AGGRESSIVE NON-HODGKIN LYMPHOMA (NHL) STAGES III AND IV- TREATMENT IMPACT OVER RELAPSE AND SURVIVAL, AT THE MEXICAN-NATIONAL CANCER ...

    Nov 1, 2008, 00:00

  • PMC22 THE IMPACT OF COMORBIDITY BURDEN AND AGE ON PREFERENCE-BASED HRQL IN THE UNITED STATES

    Nov 1, 2008, 00:00

  • PCV14 CENTRALISED PAN-EUROPEAN SURVEY ON THE UNDER-TREATMENT OF HYPERCHOLESTEROLEMIA IN PATIENTS USING LIPID LOWERING DRUGS (CEPHEUS-GREECE

    Nov 1, 2008, 00:00

  • PIN22 COST-EFFECTIVENESS ANALYSIS OF VACCINATION AGAINST ROTAVIRUS WITH RIX4414 IN FRANCE

    Nov 1, 2008, 00:00

  • PIH19 THE ASSOCIATION OF BODY MASS INDEX ON HEALTH RELATED QUALITY OF LIFE IN THE GENERAL ADULT POPULATION IN ENGLAND

    Nov 1, 2008, 00:00

  • EE3 VARIATION IN DIRECT MEDICAL COSTS BY DISEASE SEVERITY AMONG PERSONS WITH CHRONIC HEPATITIS CVIRUS

    Nov 1, 2008, 00:00

  • PDB40 COST-UTILITY OF INSULIN GLARGINE COMPARED TO NPH IN TYPE DM1 FROM A PUBLIC PAYER PERSPECTIVE IN POLAND

    Nov 1, 2008, 00:00

  • PSY41 REVIEW OF HOME READINESS INSTRUMENTS TO ASSESS RECOVERY POST-SURGERY

    Nov 1, 2008, 00:00

  • PMH19 PHARMACOECONOMIC POSITIONING OF SERTINDOLE AMONG ANTIPSYCHOTICS IN THE MANAGEMENT OF SCHIZOPHRENIA IN NORWAY

    Nov 1, 2008, 00:00

  • PMC47 A STUDY OF THE KEY FACTORS INFLUENCING THE PATIENT SATISFACTION IN INPATIENT AND OUTPATIENT SETTINGS

    Nov 1, 2008, 00:00

  • PHC4 COST-EFFECTIVENESS OF HARMONIC SCALPEL USE VERSUS CONVENTIONALTOTAL THYROIDECTOMY

    Nov 1, 2008, 00:00

  • PDB23 COST-EFFECTIVENESS OF SOMATROPIN (NORDITROPIN) FOR THE TREATMENT OF GROWTH HORMONE DEFICIENT (GHD) CHILDREN IN A SWEDISH SETTING

    Nov 1, 2008, 00:00

  • PSS21 ADMINISTRATIVE PREVALENCE OF PSORIASIS IN GERMANY

    Nov 1, 2008, 00:00

  • PCN76 HEALTH-RELATED QUALITY OF LIFE EVALUATION IN ROMANIAN CANCER PATIENTS

    Nov 1, 2008, 00:00

  • PCV21 EFFECT OF WEATHER CONDITIONS ON THE MORTALITY OF HEART ATTACKS IN HUNGARY

    Nov 1, 2008, 00:00

  • PMH16 THE COST-EFFECTIVENESS OF PALIPERIDONE ER IN ACUTE PHASE OF SCHIZOPHRENIA IN TURKEY

    Nov 1, 2008, 00:00

  • PIN31 COST-MINIMIZATION ANALYSIS OF ETRAVIRINE AND RALTEGRAVIR, TWO NEW HIV TREATMENTS FOR TREATMENT-EXPERIENCED PATIENTS

    Nov 1, 2008, 00:00

  • PHP10 PHARMACY AND HOSPITAL MARKET PERFORMANCE INDICATORS IN FINLAND 1995-2007

    Nov 1, 2008, 00:00

  • PIN28 USE OF PEGINTERFERON ALFA-2B IN CHRONIC HEPATITIS C PATIENTS FAILING PRIOR THERAPY- A COSTEFFECTIVENESS ANALYSIS

    Nov 1, 2008, 00:00

  • PCV51 SINGLE PILL AMLODIPINE/ATORVASTATIN IS COST-EFFECTIVE FOR THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE IN KOREA

    Nov 1, 2008, 00:00

  • EE6 COST-EFFECTIVENESS OF THE ADDITION OF RITUXIMAB TO FIRST-LINE CHEMOTHERAPY TREATMENT REGIMENS IN PATIENTS WITH ADVANCED FOLLICULAR LYMPHOMA IN THE UK

    Nov 1, 2008, 00:00

  • PCN55 MANAGAMENT COSTS OF PATIENTS WITH VULVAR AND VAGINAL CANCER IN FRANCE

    Nov 1, 2008, 00:00

  • PG129 INDIVIDUAL AND SOCIETAL PREFERENCE SCORES BOTH IDENTIFY ACTIVE INFLAMMATORY BOWEL DISEASE (IBD) IN GERMANY

    Nov 1, 2008, 00:00

  • PIN7 PHARMACOGENOMICS- RELEVANCE AND APPLICABILITY IN POST-GENOMIC ERA (HIV-THERAPY)

    Nov 1, 2008, 00:00

  • PHP49 ANALYSIS OF FACTORS ASSOCIATED WITH REIMBURSEMENT DECISION MAKING IN HEALTHTECHNOLOGY ASSESSMENT AGENCIES (HTA)

    Nov 1, 2008, 00:00

  • PMH13 COST-UTILITY AND BUDGET IMPACT OF SERTINDOLE IN THE TREATMENT OF SCHIZOPHRENIA IN POLAND

    Nov 1, 2008, 00:00

  • PCV96 ACCEPTABILITY OF TECHNOLOGICAL TREATMENT AND THE EFFECT OF RESPONDENT CHARACTERISTICS ON TREATMENT PREFERENCE

    Nov 1, 2008, 00:00

  • PMS61 SHORT-TERM OUTCOMES AND HRQOL AFTER PEDIATRIC EMERGENCY DEPARTMENT (PED) TREATMENT OF MINOR INJURY- A PILOT STUDY

    Nov 1, 2008, 00:00

  • PMC41 METHODOLOGICAL ISSUES IN THE LITERATURE ON COSTS OF NON-COMPLIANCE IN CHRONIC DISEASES

    Nov 1, 2008, 00:00

  • PCN91 TREATMENT PREFERENCE AND WILLINGNESS-TO-PAY (WTP) FOR METHYLNALTREXONE, A NOVEL PERIPHERAL OPIOID ANTAGONIST FOR OPIOID INDUCED CONSTIPATION

    Nov 1, 2008, 00:00

  • PRS17 COMPARISON OF OUTPATIENT AND INPATIENT COSTS OF MODERATE AND SEVERE EXACERBATIONS OF COPD IN POLAND IN 2007

    Nov 1, 2008, 00:00

  • PIH20 WEIGHT-RELATED MORBIDITY AND FAMILY DISRUPTION FOLLOWING PEDIATRIC EMERGENCY DEPARTMENT TREATMENT (PED) OF ACUTE MINOR INJURY

    Nov 1, 2008, 00:00

  • PMS67 HEALTH GAINS FOREGONE DUETO THE SUSTAINED DELAY OF ADEQUATE UTILIZATION OF EVIDENCE BASED TREATMENTS- THE CASE OF BISPHOSPHONATES FOR THE TREATMENT OF OSTEOPOROSIS

    Nov 1, 2008, 00:00

  • PG124 FURTHER VALIDATION OF THE GASTROINTESTINAL SHORT FORM QUESTIONNAIRE (GSFQ) IN THE SPANISH POPULATION

    Nov 1, 2008, 00:00

  • PCN92 VALUE OF ALOPECIA FOR LUNG CANCER PATIENT TREATED BY SECOND LINE CHEMOTHERAPY- A WILLINGNESS TO PAY STUDY

    Nov 1, 2008, 00:00

  • PCV20 PREDICTED CARDIOVASCULAR EVENT REDUCTION WITH THE CO-ADMINISTRATION OF FENOFIBRIC ACID AND STATINS IN A DYSLIPIDEMIA PATIENT COHORT

    Nov 1, 2008, 00:00

  • PMC62 UNIVERSAL TRANSLATION AND NEUROPSYCHOLOGICAL COMPARISONS OF PATIENTS FROM US-MEXICO BORDER REGION AND SPAIN

    Nov 1, 2008, 00:00

  • PCN84 THE PATIENT-REPORTED OUTCOMES MEASUREMENT INFORMATION SYSTEM CANCER PAIN ITEM BANK (PROMIS-CA PAIN)

    Nov 1, 2008, 00:00

  • PCN27 ECONOMIC EVALUATION OF A TOBACCO CESSATION PROGRAM AT A MAJOR CANCER CENTER

    Nov 1, 2008, 00:00

  • PCV37 ENOXAPARIN IS COST-SAVING AS PROPHYLACTIC THERAPY VERSUS UNFRACTIONATED HEPARIN OR NO PROPHYLAXIS IN HOSPITALISED MEDICAL PATIENTS

    Nov 1, 2008, 00:00

  • PMH44 LINGUISTIC VALIDATION, SENSITIVITY AND SPECIFICITY OF THE SCALE 'DEPRESSION IN THE MEDICALLY ILL-18'

    Nov 1, 2008, 00:00

  • PCN8 QUALITY OF LIFE-ADJUSTED SURVIVAL FOR FIRST LINE TREATMENT WITH RITUXIMAB PLUS CYCLOPHOSPHAMIDE AND VINCRISTINE (CVP) VERSUS CVP ALONE FOR PATIENTS WITH ADVANCED FOLLICULAR LYMPHOMA

    Nov 1, 2008, 00:00

  • PCN80 PATIENT REPORTED QUALITY OF LIFE IN CANCER PATIENTS ON OPIOID THERAPY IS INFLUENCED BY CONSTIPATION

    Nov 1, 2008, 00:00

  • PMH6 A SYSTEMATIC REVIEW ON THE EPIDEMIOLOGY AND SOCIOECONOMIC BURDEN OF BIPOLAR DISORDER IN EUROPE

    Nov 1, 2008, 00:00

  • PSS10 SENSITIVE SKIN IN EUROPE- AN EPIDEMIOLOGICAL APPROACH

    Nov 1, 2008, 00:00

  • PUK12 A COST-UTILITY ANALYSIS OF SOLIFENACIN 5 MG AND 10 MGVERSUS FESOTERODINE 4 MG AND 8 MG IN THE PHARMACOLOGICAL TREATMENT OF PATIENTS WITH OVERACTIVE BLADDER (OAB) IN THE UK NHS

    Nov 1, 2008, 00:00

  • PIN12 COST-EFFECTIVENESS OF CERVARIX, A PROPHYLACTIC CERVICAL CANCERVACCINE, IN SPAIN

    Nov 1, 2008, 00:00

  • PCV107 CLOPIDOGREL PATTERNS OF USE IN ACUTE CORONARY SYNDROME PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION IN FIVE EUROPEAN COUNTRIES

    Nov 1, 2008, 00:00

  • PRS31 A SURVEY OF THE BURDEN OF ALLERGIC RHINITIS IN EUROPE

    Nov 1, 2008, 00:00

  • PMC57 DISCONTINUOUS COST MEASUREMENT- HOWTO FILL IN THE GAPS?

    Nov 1, 2008, 00:00

  • PCV64 INDEX, FOLLOW-UP AND TOTAL HOSPITALIZATION COSTS IN PATIENTS WITH ACUTE CORONARY SYNDROMES UNDERGOING PLANNED PERCUTANEOUS CORONARY INTERVENTION TREATED WITH PRASUGREL VS. CLOPIDOGREL IN THE TRITON-TIMI 38 TRIAL

    Nov 1, 2008, 00:00

  • PND31 DESCRIPTIVE STUDY OF THE PHARMACOLOGICAL TREATMENTS USED IN PATIENTS WITH DEPRESSION IN PARKINSONS DISEASE (PD)

    Nov 1, 2008, 00:00

  • PIN34 COMPARISON OF GENERIC AND BRAND NAME ANTIBIOTIC USAGE IN TURKEY

    Nov 1, 2008, 00:00

  • PDB17 A COMPARISON OF COSTS AMONG PATIENTS WITH TYPE 2 DIABETESWHO INITIATED THERAPY WITH EXENATIDE OR INSULIN GLARGINE

    Nov 1, 2008, 00:00

  • PCV34 COST-EFFECTIVENESS OF GADOFOSVESET-ENHANCED MAGNETIC RESONANCE (MR) ANGIOGRAPHY FOR THE PATIENTS WITH CHRONIC PERIPHERAL ARTERIAL OBSTRUCTIVE DISEASE (PAOD) IN KOREA

    Nov 1, 2008, 00:00

  • PUK7 A TEN-YEAR HORIZON COST-EFFECTIVENESS ANALYSIS OF THE SPANISH INTEGRATED RENAL REPLACEMENT THERAPY PROGRAM

    Nov 1, 2008, 00:00

  • PCN74 A SERVICE EVALUATION TO COMPARE SECONDARY CARE RESOURCE USE BETWEEN XELOX AND FOLFOX-6 REGIMENS IN THE TREATMENT OF METASTATIC COLORECTAL CANCER (MCRC) FROM A UK NATIONAL HEALTH SERVICE (NHS) PERSPECTIVE

    Nov 1, 2008, 00:00

  • PMS36 COST OF THERAPY OF TUMOR NECROSIS FACTOR BLOCKING AGENTS IN PATIENTS WITH RHEUMATOID ARTHRITIS IN ITALY

    Nov 1, 2008, 00:00

  • PCN87 HEALTH-RELATED QUALITY OF LIFE (HRQOL) AND COLORECTAL CANCER (CRC) SYMPTOMS IN METASTATIC CRC- PANITUMUMAB PLUS BEST SUPPORTIVE CARE (BSC) VS. BSC ALONE BY KRASTUMOR STATUS

    Nov 1, 2008, 00:00

  • EE7 ECONOMIC ANALYSIS OF PROPHYLACTIC CERVICAL CANCERVACCINATION IN ITALY- THE NATIONAL AND REGIONAL LEVEL

    Nov 1, 2008, 00:00

  • PCV53 DECISION ANALYTIC MODEL FOR GENETIC TESTING IN THE MANAGEMENT OF WARFARIN ANTICOAGULATION TREATMENT FOR HOSPITALIZED PATIENTS

    Nov 1, 2008, 00:00

  • PMC63 SYSTEMATIC REVIEW RELIABILITY- SENSITIVITY AND SPECIFICITY OF ONEVS.TWO REVIEWS

    Nov 1, 2008, 00:00

  • PIN46 HEALTH-RELATED QUALITY OF LIFE AMONG PATIENTS WITH VENOUS LEG ULCER

    Nov 1, 2008, 00:00

  • PCN101 RELATIONSHIP BETWEEN HEALTH CARE SUPPLY AND MAMMOGRAPHY SCREENING?

    Nov 1, 2008, 00:00

  • PHP28 A COMPARISON OF HIGH-COST HEALTH CARE PROGRAMS AVAILABLE IN THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM

    Nov 1, 2008, 00:00

  • PCV18 EFFECT OF ENVIRONMENTAL TEMPERATURE AND WORKDAYS ON HEART ATTACK FIGURES

    Nov 1, 2008, 00:00

  • PMS34 HEALTH ECONOMIC EVALUATION OF OUTPATIENT MANAGEMENT OF FIBROMYALGIA IN FRANCE

    Nov 1, 2008, 00:00

  • PND10 BURDEN OF DISEASE IN MODERATE ALZHEIMER DISEASE PATIENTS WITH DEPRESSION IN SPAIN (IDEAL STUDY)

    Nov 1, 2008, 00:00

  • PSY64 PATIENT-REPORTED OUTCOMES (PROS) AND ECONOMICS IN PATIENTS WITH BACK PAIN IN GERMANY

    Nov 1, 2008, 00:00
  • «
  • 151
  • 152
  • 153
  • 154
  • 155 (current)
  • 156
  • 157
  • 158
  • 159
  • 160
  • »